Meta-analysis of drug efficacy in adult vs pediatric trials of patients with PGTC seizures
Por:
Nordli DR, Bagiella E, Arzimanoglou A, Wang J, Kumar D, Laurenza A and French J
Publicada:
28 abr 2020
Ahead of Print:
1 abr 2020
Categoría:
Neurology (clinical)
Resumen:
Objective A meta-analysis of published studies was performed to determine whether the efficacy of antiseizure drugs in adults with primary generalized tonic-clonic seizures (PGTCS) is comparable with that in the pediatric population (2-12 years of age). Methods Electronic searches were conducted in EMBASE, Medline, and the Cochrane Central Register of Controlled Trials for clinical trials of PGTCS in adults and children 2-12 years of age. Neurologists used standardized search and study evaluations to select eligible trials. Median percent reduction in seizure frequency from baseline and >= 50% responder rates were used to compare drug efficacy in adults and children. Results Among 7 adjunctive-therapy PGTCS trials in adults and children (2-12 years of age) that met evaluation criteria, effect sizes were consistent between adults and children for lamotrigine and topiramate. The baseline-subtracted median percent seizure reduction in seizure frequency ranged from 50.0% to 79.7% in children and 57.0% to 64.0% in adults. The >= 50% responder rate was similar between children and adults in a topiramate study (50% in children compared with 58% in adults). Conclusions This meta-analysis supports the use of drug response from antiseizure drug clinical trials for PGTCS in adults to predict comparable treatment response in children 2-12 years of age with PGTCS.
Filiaciones:
Nordli DR:
From the University of Chicago (D.R.N.), IL
Mount Sinai School of Medicine (E.B.), New York, NY
Department of Pediatric Clinical Epileptology, Sleep Disorders and Functional Neurology (A.A.), University Hospitals of Lyon (HCL), Member of the European Reference Network EpiCARE, Lyon, France
Paediatric Epilepsy Unit (A.A.), Hospital Sant Joan de Déu, Member of the European Reference Network EpiCARE and Universitat de Barcelona, Spain
Eisai Inc. (J.W., D.K., A.L.), Woodcliff Lake, NJ
and NYU Comprehensive Epilepsy Center (J.F.), New York, NY.
Bagiella E:
From the University of Chicago (D.R.N.), IL
Mount Sinai School of Medicine (E.B.), New York, NY
Department of Pediatric Clinical Epileptology, Sleep Disorders and Functional Neurology (A.A.), University Hospitals of Lyon (HCL), Member of the European Reference Network EpiCARE, Lyon, France
Paediatric Epilepsy Unit (A.A.), Hospital Sant Joan de Déu, Member of the European Reference Network EpiCARE and Universitat de Barcelona, Spain
Eisai Inc. (J.W., D.K., A.L.), Woodcliff Lake, NJ
and NYU Comprehensive Epilepsy Center (J.F.), New York, NY
Arzimanoglou A:
From the University of Chicago (D.R.N.), IL
Mount Sinai School of Medicine (E.B.), New York, NY
Department of Pediatric Clinical Epileptology, Sleep Disorders and Functional Neurology (A.A.), University Hospitals of Lyon (HCL), Member of the European Reference Network EpiCARE, Lyon, France
Paediatric Epilepsy Unit (A.A.), Hospital Sant Joan de Déu, Member of the European Reference Network EpiCARE and Universitat de Barcelona, Spain
Eisai Inc. (J.W., D.K., A.L.), Woodcliff Lake, NJ
and NYU Comprehensive Epilepsy Center (J.F.), New York, NY
Wang J:
From the University of Chicago (D.R.N.), IL
Mount Sinai School of Medicine (E.B.), New York, NY
Department of Pediatric Clinical Epileptology, Sleep Disorders and Functional Neurology (A.A.), University Hospitals of Lyon (HCL), Member of the European Reference Network EpiCARE, Lyon, France
Paediatric Epilepsy Unit (A.A.), Hospital Sant Joan de Déu, Member of the European Reference Network EpiCARE and Universitat de Barcelona, Spain
Eisai Inc. (J.W., D.K., A.L.), Woodcliff Lake, NJ
and NYU Comprehensive Epilepsy Center (J.F.), New York, NY
Kumar D:
From the University of Chicago (D.R.N.), IL
Mount Sinai School of Medicine (E.B.), New York, NY
Department of Pediatric Clinical Epileptology, Sleep Disorders and Functional Neurology (A.A.), University Hospitals of Lyon (HCL), Member of the European Reference Network EpiCARE, Lyon, France
Paediatric Epilepsy Unit (A.A.), Hospital Sant Joan de Déu, Member of the European Reference Network EpiCARE and Universitat de Barcelona, Spain
Eisai Inc. (J.W., D.K., A.L.), Woodcliff Lake, NJ
and NYU Comprehensive Epilepsy Center (J.F.), New York, NY
Laurenza A:
From the University of Chicago (D.R.N.), IL
Mount Sinai School of Medicine (E.B.), New York, NY
Department of Pediatric Clinical Epileptology, Sleep Disorders and Functional Neurology (A.A.), University Hospitals of Lyon (HCL), Member of the European Reference Network EpiCARE, Lyon, France
Paediatric Epilepsy Unit (A.A.), Hospital Sant Joan de Déu, Member of the European Reference Network EpiCARE and Universitat de Barcelona, Spain
Eisai Inc. (J.W., D.K., A.L.), Woodcliff Lake, NJ
and NYU Comprehensive Epilepsy Center (J.F.), New York, NY
French J:
From the University of Chicago (D.R.N.), IL
Mount Sinai School of Medicine (E.B.), New York, NY
Department of Pediatric Clinical Epileptology, Sleep Disorders and Functional Neurology (A.A.), University Hospitals of Lyon (HCL), Member of the European Reference Network EpiCARE, Lyon, France
Paediatric Epilepsy Unit (A.A.), Hospital Sant Joan de Déu, Member of the European Reference Network EpiCARE and Universitat de Barcelona, Spain
Eisai Inc. (J.W., D.K., A.L.), Woodcliff Lake, NJ
and NYU Comprehensive Epilepsy Center (J.F.), New York, NY
Green Published, hybrid
|